Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Costantine Albany

Showing results (41-50 of 65) with videos related to

Pageof 7
Sort By:
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|June 6, 2020
Cisplatin-associated neuropathy characteristics compared with those associated with other neurotoxic chemotherapy agents (Alliance A151724)Costantine Albany, Travis Dockter, Eric Wolfe, et al.
Urologic Oncology|September 9, 2019
The prognostic impact of different tumor marker levels in nonseminomatous germ cell tumor patients with intermediate prognosis: A registry of the International Global Germ Cell Tumor Collaborative Group (G3)Christoph Seidel, Gedske Daugaard, Alexey Tryakin, et al.
Cancer Chemotherapy and Pharmacology|October 15, 2015
Phase 2 trial of the topoisomerase II inhibitor, amrubicin, as second-line therapy in patients with metastatic urothelial carcinomaMatthew D Galsky, Noah M Hahn, Bryan Wong, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|February 4, 2016
Phase II study of fosaprepitant + 5HT3 receptor antagonist + dexamethasone in patients with germ cell tumors undergoing 5-day cisplatin-based chemotherapy: a Hoosier Cancer Research Network studyNabil Adra, Costantine Albany, Mary J Brames, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|September 4, 2021
Correction to: Cisplatin-associated neuropathy characteristics compared with those associated with other neurotoxic chemotherapy agents (Alliance A151724)Costantine Albany, Travis Dockter, Eric Wolfe, et al.
Epigenetics|October 31, 2020
Hypermethylation and global remodelling of DNA methylation is associated with acquired cisplatin resistance in testicular germ cell tumoursZeeshan Fazal, Ratnakar Singh, Fang Fang, et al.
Cancer Medicine|November 2, 2020
A phase 1 study of combined guadecitabine and cisplatin in platinum refractory germ cell cancerCostantine Albany, Zeeshan Fazal, Ratnakar Singh, et al.
Future Oncology (London, England)|June 4, 2016
Neoadjuvant chemotherapy in urothelial bladder cancer: impact of regimen and variant histologyHristos Z Kaimakliotis, M Francesca Monn, Jane S Cho, et al.
Investigational New Drugs|May 25, 2021
Phase II trial of brentuximab vedotin in relapsed/refractory germ cell tumorsRyan Ashkar, Darren R Feldman, Nabil Adra, et al.
Urologic Oncology|June 26, 2017
Testicular cancer: The usage of central review for pathology diagnosis of orchiectomy specimensSaul E Harari, Daniel J Sassoon, David S Priemer, et al.
Pageof 7

Showing results (41-50 of 65) with videos related to

Sort By:
Pageof 7
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|June 6, 2020
Cisplatin-associated neuropathy characteristics compared with those associated with other neurotoxic chemotherapy agents (Alliance A151724)Costantine Albany, Travis Dockter, Eric Wolfe, et al.
Urologic Oncology|September 9, 2019
The prognostic impact of different tumor marker levels in nonseminomatous germ cell tumor patients with intermediate prognosis: A registry of the International Global Germ Cell Tumor Collaborative Group (G3)Christoph Seidel, Gedske Daugaard, Alexey Tryakin, et al.
Cancer Chemotherapy and Pharmacology|October 15, 2015
Phase 2 trial of the topoisomerase II inhibitor, amrubicin, as second-line therapy in patients with metastatic urothelial carcinomaMatthew D Galsky, Noah M Hahn, Bryan Wong, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|February 4, 2016
Phase II study of fosaprepitant + 5HT3 receptor antagonist + dexamethasone in patients with germ cell tumors undergoing 5-day cisplatin-based chemotherapy: a Hoosier Cancer Research Network studyNabil Adra, Costantine Albany, Mary J Brames, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|September 4, 2021
Correction to: Cisplatin-associated neuropathy characteristics compared with those associated with other neurotoxic chemotherapy agents (Alliance A151724)Costantine Albany, Travis Dockter, Eric Wolfe, et al.
Epigenetics|October 31, 2020
Hypermethylation and global remodelling of DNA methylation is associated with acquired cisplatin resistance in testicular germ cell tumoursZeeshan Fazal, Ratnakar Singh, Fang Fang, et al.
Cancer Medicine|November 2, 2020
A phase 1 study of combined guadecitabine and cisplatin in platinum refractory germ cell cancerCostantine Albany, Zeeshan Fazal, Ratnakar Singh, et al.
Future Oncology (London, England)|June 4, 2016
Neoadjuvant chemotherapy in urothelial bladder cancer: impact of regimen and variant histologyHristos Z Kaimakliotis, M Francesca Monn, Jane S Cho, et al.
Investigational New Drugs|May 25, 2021
Phase II trial of brentuximab vedotin in relapsed/refractory germ cell tumorsRyan Ashkar, Darren R Feldman, Nabil Adra, et al.
Urologic Oncology|June 26, 2017
Testicular cancer: The usage of central review for pathology diagnosis of orchiectomy specimensSaul E Harari, Daniel J Sassoon, David S Priemer, et al.
Pageof 7